2014年2月2日星期日

RAI on Small Differentiated Thyroid Cancer Having Microscopic Extrathyroidal Extension


Effects of Low-Dose and High-Dose Postoperative Radioiodine Therapy on the Clinical Outcome in Patients with Small Differentiated Thyroid Cancer Having Microscopic Extrathyroidal Extension

Background: It is unclear whether differentiated thyroid cancer (DTC) patients classified as intermediate risk based on the presence of microscopic extrathyroidal extension (ETE) should be treated with low or high doses of radioiodine (RAI) after surgery. We evaluated success rates and long-term clinical outcomes of patients with DTC of small tumor size, microscopic ETE, and no cervical lymph node (LN) metastasis treated either with a low (1.1 GBq) or high RAI dose (5.5 GBq).
Methods: This is a retrospective analysis of a historical cohort from 2000 to 2010 in a tertiary referral hospital. A total of 176 patients with small (≤2 cm) DTC, microscopic ETE, and no cervical LN metastasis were included. Ninety-six patients were treated with 1.1 GBq (LO group) and 80 patients with 5.5 GBq (HI group). Successful RAI therapy was defined as (i) negative stimulated thyroglobulin (Tg) in the absence of Tg antibodies, and (ii) absence of remnant thyroid tissue and of abnormal cervical LNs on ultrasonography. Clinical recurrence was defined as the reappearance of disease after ablation, which was confirmed by cytologically or pathologically proven malignant tissue or of distant metastatic lesions.
Results: There was no significant difference in the rate of successful RAI therapy between the LO and HI group (p=0.75). In a subgroup analysis based on tumor size, success rates were not different between the LO group (34/35, 97%) and the HI group (50/56, 89%) in patients with a tumor size of 1–2 cm (p=0.24). In patients with smaller tumor size (≤1 cm), there was no significant difference in success rates between the LO (59/61, 97%) and HI group (22/24, 92%; p=0.30). No patient had clinical recurrences in either group during the median 7.2 years of follow-up.
Conclusions: Low-dose RAI therapy is sufficient to treat DTC patients classified as intermediate risk just by the presence of microscopic ETE.
===============

Users who read this article also read

no access
Pedro Weslley Rosário, Maria Regina Calsolari
Thyroid. January 2014, ahead of print.
Abstract | Full Text PDF or HTML | Reprints | Permissions
no access
Pedro Weslley Rosario, Gabriela Franco Mourão, Juan Bernard Nascimento dos Santos, Maria Regina Calsolari
Thyroid. December 2013, ahead of print.
Abstract | Full Text PDF or HTML | Reprints | Permissions
no access
Iain J. Nixon, Ian Ganly, Snehal G. Patel, Frank L. Palmer, Monica M. Di Lorenzo, Ravinder K. Grewal, Steven M. Larson, R. Michael Tuttle, Ashok Shaha, Jatin P. Shah
Thyroid. June 2013: 683-694.
Abstract | Full Text PDF or HTML | Reprints | Permissions
no access
Maria Roseneide dos Santos Torres, Sebastião Horácio Nóbrega Neto, Rosalina Jenner Rosas, Aline Lemos Barros Martins, André Luis Correia Ramos, Thomaz Rodrigues Porto da Cruz
Thyroid. January 2014: 7-18.
Abstract | Full Text PDF or HTML | Reprints | Permissions
no access
Frederik A. Verburg, Markus Luster, Cristina Cupini, Luca Chiovato, Leonidas Duntas, Rossella Elisei, Ulla Feldt-Rasmussen, Harald Rimmele, Ettore Seregni, Johannes W.A. Smit, Christian Theimer, Luca Giovanella
Thyroid. October 2013: 1211-1225.
Abstract | Full Text PDF or HTML | Reprints | Permissions
no access
Douglas S. Ross, R. Michael Tuttle
Thyroid. January 2014: 3-6.
First Page | Full Text PDF or HTML | Reprints | Permissions

没有评论:

发表评论